Generic Name and Formulations:
Oxandrolone 2.5mg+, 10mg; tabs (+scored).
Indications for OXANDRIN:
As an adjunct to promote weight gain after extensive surgery, chronic infections, severe trauma, and without definite cause, to offset protein catabolism associated with prolonged corticosteroid administration, and for relief of osteoporotic bone pain.
Individualize. 2.5–20mg daily given in 2–4 divided doses. Treat for 2–4 weeks; may repeat intermittently as needed. Elderly: 5mg twice daily.
≤0.1mg/kg/day; may repeat intermittently as needed.
Breast (women with hypercalcemia, men) or prostate carcinoma. Nephrosis. Hypercalemia. Pregnancy (Cat.X).
Risk of peliosis hepatis, liver cell tumors, blood lipid changes associated with atherosclerosis. Discontinue if cholestatic hepatitis, jaundice, abnormal liver function tests, or hypercalcemia occurs. Cardiovascular disease. COPD. Edematous conditions. Hepatic or renal dysfunction. Monitor hepatic function, serum lipids, Hgb/Hct, and bone age (children) periodically. Monitor for signs of virilization in women; discontinue if mild virilism occurs to prevent irreversible condition. Elderly. Young children. Nursing mothers: not recommended.
May potentiate warfarin (monitor INR/PT), oral hypoglycemics. Increased risk of edema with ACTH, corticosteroids. May suppress clotting factors II, V, VII and X. May decrease thyroxine-binding globulin and radioactive iodine uptake.
Peliosis hepatis, premature epiphyseal closure in children, edema, dyslipidemia, hepatic carcinoma, prostatic hypertrophy or carcinoma, gynecomastia, priapism, oligospermia, jaundice, hirsutism, virilization, menstrual irregularities, male pattern baldness, acne, polycythemia, excitation, depression, altered libido, fluid and electrolyte disturbances, decreased glucose tolerance.
Tabs 2.5mg—100; 10mg—60
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML